DSIP: what an experimental sleep peptide can and can't offer

How DSIP (Delta Sleep-Inducing Peptide) works

DSIP is a nine-amino-acid peptide first isolated in the 1970s during animal sleep research. In animal studies it increased slow-wave (delta) sleep, though its effects followed an unusual U-shaped dose pattern. How it acts in the human brain, whether it reaches the brain in meaningful amounts when injected, and whether it has a dedicated receptor remain unclear.

Who it’s for, and who it isn’t

What’s included

• Online sleep-focused assessment with a licensed clinician
• Screening for sleep apnea symptoms, mood, medications, alcohol and hormone-related sleep changes
• Guidance on first-line options such as CBT-I and sleep routines
• Prescription only if appropriate and if a licensed pharmacy can lawfully dispense it
• Follow-up to review sleep and decide whether to continue
• No membership fee (labs priced separately)

Possible side effects

• Injection-site redness, itching or bruising
• Other side effects have not been measured reliably in people; report anything new to your clinician
• Possible immune reactions to peptide impurities, a concern FDA staff raised
• Long-term effects in people are unknown

This isn’t a complete list. Your clinician reviews risks, interactions and warnings with you before prescribing. In an emergency, call 911.

What the evidence says

Research on DSIP peaked in the 1970s and 1980s, with small and mixed human studies. A 1984 review described sleep-promoting effects across several species but also inconsistent, U-shaped dose responses. In July 2026, FDA staff told the advisory committee that emideltide lacks adequate safety and effectiveness data for insomnia, narcolepsy and opioid withdrawal.

What DSIP is

DSIP stands for delta sleep-inducing peptide; its official nonproprietary name is emideltide. It is a chain of nine amino acids that researchers isolated in the 1970s while looking for natural sleep signals in the blood.

Animal studies found it could increase deep, slow-wave sleep. That early promise never turned into an approved medicine, and decades later there is still no well-designed modern trial in people with insomnia.

What the evidence says about sleep

A 1984 scientific review summarized what was known: DSIP promoted delta sleep in several species, DSIP-like material was found in the brain and blood, and responses followed a U-shaped curve, where both too little and too much had less effect. That kind of pattern makes dosing hard to predict.

Human studies from that era were small and their results were mixed. The evidence is not strong enough to say DSIP improves sleep for midlife adults, and we will not suggest otherwise.

The July 2026 FDA advisory committee decision

DSIP was previously in Category 2 of the FDA's interim lists of bulk substances for compounding. In April 2026 its nomination was withdrawn and the FDA moved it to its nominated-but-withdrawn list. That change was not a safety finding.

On July 24, 2026, the FDA's Pharmacy Compounding Advisory Committee considered emideltide for opioid withdrawal, chronic insomnia and narcolepsy. The committee voted 6 to 7, with one abstention, against recommending it for the 503A bulks list. FDA staff said the substance was not adequately characterized, could carry peptide-related impurities, lacked safety and effectiveness data, and that approved treatments already exist.

DSIP is not FDA-approved, and its path to lawful compounding is less clear than for peptides the committee endorsed. HealifyMD only arranges a prescription where a licensed pharmacy confirms it can lawfully dispense the product under current federal and state rules.

Sleep assessment comes first

Poor sleep in your 40s and 50s often has a cause that can be found. Sleep apnea can show up as snoring, gasping, morning headaches, waking to urinate, or simply feeling unrefreshed. In women it often looks like fatigue and insomnia rather than loud snoring.

Your clinician also looks at perimenopause and menopause symptoms such as night sweats, alcohol timing, caffeine, pain, mood, and medicines that disturb sleep. Some of these are best handled with hormone therapy, a sleep study or a change in medication rather than a peptide.

Proven options worth trying

The National Heart, Lung, and Blood Institute notes that cognitive behavioral therapy for insomnia (CBT-I) is usually recommended as the first treatment for long-term insomnia. It is a structured 6- to 8-week program that can be done online.

Several FDA-approved sleep medicines exist when CBT-I is not enough. Your clinician can talk through how DSIP compares with these options, which have far more evidence behind them.

How we judge whether it is helping

Sleep is easy to misjudge from memory, so your clinician will usually ask you to keep a simple sleep diary for a couple of weeks before and after any change. It records bedtime, time to fall asleep, night wakings, final wake time, alcohol and caffeine, and how rested you feel. A wearable can add context but is not required.

At follow-up you compare the two periods. If your sleep has not improved in a way that matters to you, or you notice anything that worries you, the plan is to stop and focus on other options. Because the evidence for DSIP is so limited, a short, closely watched trial is the most it should ever be.

Compounded, not FDA-approved

If prescribed, DSIP is a compounded preparation made for you by a licensed U.S. pharmacy. Compounded medicines are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality. Your clinician sets dosing; we do not publish home dosing schedules.

The price starts at $200/month, or $350 for two months ($175/month), with no membership fee, confirmed during your eligibility review. Labs are priced separately.

Go deeper on DSIP (Delta Sleep-Inducing Peptide)